Matthew is Rare Disease Medical Director Pfizer UK responsible for medical affairs activities in the UK across Pfizer’s broad portfolio of inline and pipeline assets.
Prior to his current position Matthew was Pfizer UK Health ＆ Value HTA team leader, where he was responsible for all UK HTA related activity across the Vaccines, Internal Medicine and Generic medicines businesses. Prior to this Matthew was Medical Affairs manager in the UK Cardiovascular team at Pfizer.
Matthew obtained his medical degree from Imperial College London following which he completed his early training in general medicine before embarking on specialist training in Cardiology. He spent 5 years at St Thomas’ hospital London and Kings College London combining clinical training with a PhD in clinical research and cardiovascular physiology. During this period he was actively involved in the design and execution of several multi-centre clinical trials. He has published widely in the area of cardiovascular medicine and physiology and maintains an affiliation with the research group at St Thomas /Kings College London.
Matthew is a full member of the Royal College of Physicians (MRCP), is a Member of the Faculty of Pharmaceutical Medicine (MFPM), holds a post-graduate certificate in medical education from University College London and is an honorary fellow of the Higher Education Authority (FHEA). He is a specialist trainee in Pharmaceutical Medicine.